Targeting rare and non-canonical driver variants in NSCLC – An uncharted clinical field-Reference-Cited by-同舟云学术

Targeting rare and non-canonical driver variants in NSCLC – An uncharted clinical field

Published:2021-04 Issue: Volume:154 Page:131-141
ISSN:0169-5002
Container-title:Lung Cancer
language:en
Short-container-title:Lung Cancer

Author:

Volckmar Anna-Lena^ORCID,Christopoulos Petros^ORCID,Kirchner Martina,Allgäuer Michael,Neumann Olaf^ORCID,Budczies Jan,Rempel Eugen^ORCID,Horak Peter^ORCID,Glade Julia^ORCID,Goldschmid Hannah,Seker-Cin Huriye,Brandt Regine,Kriegsmann Mark,Leichsenring Jonas,Winter Hauke,Faehling Martin,Fischer Jürgen R.,Heußel Claus Peter,Herth Felix^ORCID,Brummer Tilman,Fröhling Stefan^ORCID,Schirmacher Peter,Thomas Michael^ORCID,Endris Volker,Penzel Roland,Kazdal Daniel^ORCID,Bochtler Tilmann^ORCID,Stenzinger Albrecht

Funder

German Cancer Consortium

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference89 articles.

1. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012;Ferlay;Int. J. Cancer,2015

2. A systematic review of the clinical effectiveness of first-line chemotherapy for adult patients with locally advanced or metastatic non-small cell lung cancer;Pilkington;Thorax,2015

3. Updated analysis of KEYNOTE-024: pembrolizumab versus platinum-based chemotherapy for advanced non-small-cell lung cancer with PD-L1 tumor proportion score of 50% or Greater;Reck;J. Clin. Oncol.,2019

4. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer;Gandhi;N. Engl. J. Med.,2018

5. Five-year follow-Up of nivolumab in previously treated advanced Non-small-cell lung cancer: results from the CA209-003 study;Gettinger;J. Clin. Oncol.,2018

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Prevalence and treatment of human epidermal growth factor receptor 2-altered non-small cell lung cancer: a retrospective analysis and systematic literature review;ecancermedicalscience;2024-08-01

2. Activity of afatinib in patients with NSCLC harboring novel uncommon EGFR mutations with or without co-mutations: a case report;Frontiers in Oncology;2024-05-06

3. Evaluation of Artificial Intelligence (AI)-basedin silicotools for variant classification in clinically actionable NSCLC variants;2024-04-14

4. Analysis of rare fusions in NSCLC: Genomic architecture and clinical implications;Lung Cancer;2023-10

5. Real‐world data for precision cancer medicine—A European perspective;Genes, Chromosomes and Cancer;2023-03-09